NASHUA, N.H., Nov. 30, 2015 /PRNewswire/ -- iCAD, Inc. (Nasdaq:
ICAD) announced today that it will feature its latest solutions for
advanced image analysis and workflow tools for the early
identification of cancer at the Radiological Society of North
American (RSNA) 2015 Annual Meeting in Chicago from November
29 to December 4, 2015. The company will showcase recent
product advances including iReveal®, an automated breast density
assessment solution, PowerLook® Advanced Mammography Platform,
featuring the company's flagship advanced cancer detection product,
VeraLook® colon polyp detection technology, and new tomosynthesis*
solutions, shown as works in progress at its booth #2529-South Hall
at RSNA 2015.
The iReveal® automated breast density solution is designed to
standardize the assessment and reporting of breast density.
iReveal assists radiologists in evaluating and scoring breast
density to identify patients who may be at higher risk of
developing breast cancer. With an appearance-based approach,
iReveal uses an innovative technique that analyzes the structure,
texture, and dispersion of the fibroglandular tissue in the breast,
then calibrates the results to a density category corresponding to
the BI-RADS breast density reporting system. iCAD will also
be previewing a breast density assessment solution for
tomosynthesis*.
"The issue of breast density is rapidly emerging as a pivotal
factor in the diagnosis of breast cancer, and iReveal is
another great example of our continued focus to detect cancer
earlier, when it may be more easily treated," said Ken Ferry, CEO of iCAD. "Currently, 24 states
have adopted legislation that require patients to be notified of
their breast density. As these laws expand to other states
and perhaps nationally, it is essential for radiologists to have
access to superior technology that delivers rapid, automatic, and
reproducible breast density assessment results."
The PowerLook Advanced Mammography Platform® and VeraLook® colon
polyp detection will also be available for demonstrations at the
iCAD booth during RSNA. The PowerLook AMP solution delivers
superior performance for accurate detection of breast cancer.
VeraLook® automatically detects polyps in computed tomography
colonography (CTC) images assisting in the interpretation of CTC
exams. As a work in progress, iCAD will also be demonstrating
tomosynthesis workflow tools to support cancer detection and
increased reading efficiency.
"This has been an exciting year at iCAD where our focus on
innovation and product development have delivered some important
advances that will significantly improve cancer diagnosis and
treatment in the years ahead," Mr. Ferry added.
During RSNA, researchers will also present data supporting the
use of Radion Hub, a cloud based management platform that enables a
single radiation oncologist to remotely complete peer reviews
across multiple non-affiliated locations. The study's lead author,
Dawn Henrich, BS, CMD, will be
available to discuss the study's findings in the iCAD booth on
Tuesday, December 1 and Wednesday,
December 2.
* iCAD tomosynthesis solutions are investigational devices and
limited by Federal Law to investigational use.
About iCAD, Inc.
iCAD delivers innovative cancer
detection and radiation therapy solutions and services that enable
clinicians to find and treat cancers earlier and faster while
improving patient outcomes. iCAD offers a comprehensive range of
upgradeable computer aided detection (CAD) and workflow solutions
to support rapid and accurate detection of breast, prostate and
colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy
(eBx®) System® is a painless, non-invasive technology that delivers
high dose rate, low energy radiation, which targets cancer while
minimizing exposure to surrounding healthy tissue. The Xoft System
is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in
the body, including treatment of early-stage breast cancer,
gynecological cancers and non-melanoma skin cancer. The
comprehensive iCAD technology platforms include advanced hardware
and software as well as management services designed to support
cancer detection and radiation therapy treatments. For more
information, visit www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995
Certain statements contained
in this News Release constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve a number of known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited to the
Company's ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty
of patent protection, the impact of supply and manufacturing
constraints or difficulties, uncertainty of future sales levels,
protection of patents and other proprietary rights, the impact of
supply and manufacturing constraints or difficulties, product
market acceptance, possible technological obsolescence of products,
increased competition, litigation and/or government regulation,
changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors,
the effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company's filings with the
Securities and Exchange Commission. The words "believe",
"demonstrate", "intend", "expect", "estimate", "will", "continue",
"anticipate", "likely", "seek", and similar expressions identify
forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other
risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission,
available on the Investors section of our website at
http://www.icadmed.com and on the SEC's website at
http://www.sec.gov.
Contact:
For iCAD investor relations:
The Ruth Group
Zack Kubow, 646-536-7030
www.theruthgroup.com
iCAD@theruthgroup.com
or
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
jburns@berrypr.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/icad-featuring-new-technology-for-automated-breast-density-assessment-and-showcasing-solutions-for-tomosynthesis-at-rsna-2015-300185097.html
SOURCE iCAD, Inc.